Bovine brucellosis
1. The programmes for the eradication of bovine brucellosis submitted by Ireland, Spain, Italy, Malta, Cyprus, Portugal and the United Kingdom are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out laboratory tests, the compensation to owners for the value of their animals slaughtered subject to those programmes and the purchase of vaccine doses, and shall not exceed:
(a)
EUR 1 100 000 for Ireland;
(b)
EUR 3 000 000 for Spain;
(c)
EUR 5 000 000 for Italy;
(d)
EUR 77 000 for Cyprus;
(e)
EUR 20 000 for Malta;
(f)
EUR 1 400 000 for Portugal;
(g)
EUR 2 000 000 for the United Kingdom.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed:
(a)
for a rose bengal test
EUR 0,2 per test;
(b)
for a SAT test
EUR 0,2 per test;
(c)
for a complement fixation test
EUR 0,4 per test;
(d)
for an ELISA test
EUR 1 per test;
(e)
for animals slaughtered
EUR 375 per animal.
Bovine tuberculosis
1. The programmes for the eradication of bovine tuberculosis submitted by Ireland, Spain, Italy, Poland and Portugal are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the costs of carrying out tuberculin and gamma-interferon tests and the compensation to owners for the value of their animals slaughtered subject to those programmes, and shall not exceed:
(a)
EUR 2 000 000 for Ireland;
(b)
EUR 5 000 000 for Spain;
(c)
EUR 2 700 000 for Italy;
(d)
EUR 1 100 000 for Poland;
(e)
EUR 1 000 000 for Portugal.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed:
(a)
for a tuberculin test
EUR 1 per test;
(b)
for a gamma-interferon test
EUR 5 per test;
(c)
for animals slaughtered
EUR 375 per animal.
Ovine and caprine brucellosis
1. The programmes for the eradication of ovine and caprine brucellosis submitted by Greece, Spain, Italy, Cyprus and Portugal are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the purchase of vaccines, the cost of carrying out laboratory tests and the compensation to owners for the value of their animals slaughtered subject to those programmes, and shall not exceed:
(a)
EUR 250 000 for Greece;
(b)
EUR 4 500 000 for Spain;
(c)
EUR 4 000 000 for Italy;
(d)
EUR 75 000 for Cyprus;
(e)
EUR 1 100 000 for Portugal.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed:
(a)
for a rose bengal test
EUR 0,2 per test;
(b)
for a complement fixation test
EUR 0,4 per test;
(c)
for animals slaughtered
EUR 50 per animal.
Bluetongue in endemic or high risk areas
1. The programmes for the eradication and monitoring of bluetongue submitted by Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Estonia, Ireland, Greece, Spain, France, Italy, Latvia, Lithuania, Luxembourg, Hungary, Malta, the Netherlands, Austria, Poland, Portugal, Romania, Slovenia, Finland and Sweden are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out the laboratory tests for virological, serological and entomological surveillance and the purchase of traps and vaccines, and shall not exceed:
(a)
EUR 1 200 000 for Belgium;
(b)
EUR 5 000 for Bulgaria;
(c)
EUR 790 000 for the Czech Republic;
(d)
EUR 840 000 for Denmark;
(e)
EUR 4 100 000 for Germany;
(f)
EUR 10 000 for Estonia;
(g)
EUR 1 000 000 for Ireland;
(h)
EUR 50 000 for Greece;
(i)
EUR 16 100 000 for Spain;
(j)
EUR 19 100 000 for France;
(k)
EUR 9 000 000 for Italy;
(l)
EUR 70 000 for Latvia;
(m)
EUR 50 000 for Lithuania;
(n)
EUR 220 000 for Luxembourg;
(o)
EUR 500 000 for Hungary;
(p)
EUR 5 000 for Malta;
(q)
EUR 2 100 000 for the Netherlands;
(r)
EUR 1 500 000 for Austria;
(s)
EUR 500 000 for Poland;
(t)
EUR 3 200 000 for Portugal;
(u)
EUR 250 000 for Romania;
(v)
EUR 250 000 for Slovenia;
(w)
EUR 50 000 for Finland;
(x)
EUR 370 000 for Sweden.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed:
(a)
for an ELISA test EUR 2,5 per test;
(b)
for a PCR test EUR 10 per test;
(c)
For vaccine purchase EUR 0,3 per dose.
Salmonellosis (zoonotic salmonella) in breeding, laying and broiler flocks of Gallus gallus
1. The programmes for the control of certain zoonotic salmonella in breeding, laying and broiler flocks of Gallus gallus submitted by Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, Germany, Ireland, Greece, Spain, France, Italy, Cyprus, Latvia, Luxembourg, Hungary, Malta, the Netherlands, Austria, Poland, Portugal, Romania, Slovakia, Slovenia and the United Kingdom are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out bacteriological and serotyping tests in the framework of official sampling, the compensation to owners for the value of the birds culled and of the destroyed eggs, the purchase of vaccine doses and the laboratory tests to verify the efficiency of disinfection and shall not exceed:
(a)
EUR 850 000 for Belgium;
(b)
EUR 30 000 for Bulgaria;
(c)
EUR 1 400 000 for the Czech Republic;
(d)
EUR 75 000 for Denmark;
(e)
EUR 25 000 for Estonia;
(f)
EUR 600 000 for Germany;
(g)
EUR 40 000 for Ireland;
(h)
EUR 550 000 for Greece;
(i)
EUR 4 750 000 for Spain;
(j)
EUR 3 250 000 for France;
(k)
EUR 1 100 000 for Italy;
(l)
EUR 76 000 for Cyprus;
(m)
EUR 270 000 for Latvia;
(n)
EUR 16 000 for Luxembourg;
(o)
EUR 1 450 000 for Hungary;
(p)
EUR 110 000 for Malta;
(q)
EUR 1 700 000 for the Netherlands;
(r)
EUR 525 000 for Austria;
(s)
EUR 1 550 000 for Poland;
(t)
EUR 500 000 for Portugal;
(u)
EUR 450 000 for Romania;
(v)
EUR 625 000 for Slovakia;
(w)
EUR 25 000 for Slovenia;
(x)
EUR 20 000 for the United Kingdom.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed:
(a)
for a bacteriological test (cultivation)
EUR 5,0 per test;
(b)
for the purchase of one vaccine dose
EUR 0,05 per dose;
(c)
for serotyping of relevant isolates of Salmonella spp.
EUR 20 per test;
(d)
for the analysis to verify the efficiency of the use of disinfectants
EUR 5,0 per test;
(e)
for the culling of a breeding bird of Gallus gallus
EUR 3,5 per bird;
(f)
for the culling of a laying bird of Gallus gallus
EUR 1,5 per bird.
Classical swine fever and African swine fever
1. The programmes for the control and monitoring of:
(a)
Classical swine fever submitted by Bulgaria, Germany, France, Luxembourg, Hungary, Romania, Slovenia and Slovakia are hereby approved for the period from 1 January 2009 to 31 December 2009.
(b)
African swine fever submitted by Italy is hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out virological and serological tests of domestic pigs and wild boars and for the programmes submitted by Bulgaria, Germany, France, Romania and Slovakia also at the rate of 50 % of the costs to be incurred for the purchase and distribution of vaccines plus baits for the vaccination of wild boars and, for Romania, for the vaccination of domestic pigs as well, and shall not exceed:
(a)
EUR 200 000 for Bulgaria;
(b)
EUR 800 000 for Germany;
(c)
EUR 550 000 for France;
(d)
EUR 100 000 for Italy;
(e)
EUR 350 000 for Hungary;
(f)
EUR 5 000 for Luxembourg;
(g)
EUR 2 500 000 for Romania;
(h)
EUR 30 000 for Slovenia;
(i)
EUR 550 000 for Slovakia.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed for an ELISA test EUR 2,5 per test.
Swine vesicular disease
1. The programme for the eradication of swine vesicular disease submitted by Italy is hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the cost of laboratory tests and shall not exceed EUR 500 000.
Avian influenza in poultry and wild birds
1. The survey programmes for avian influenza in poultry and wild birds submitted by Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Estonia, Ireland, Greece, Spain, France, Italy, Cyprus, Latvia, Lithuania, Luxembourg, Hungary, Malta, the Netherlands, Austria, Poland, Portugal, Romania, Slovenia, Slovakia, Finland, Sweden and the United Kingdom are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State for the costs of carrying out laboratory tests and a lump sum for sampling of wild birds, and shall not exceed:
(a)
EUR 90 000 for Belgium;
(b)
EUR 70 000 from Bulgaria;
(c)
EUR 60 000 for the Czech Republic;
(d)
EUR 200 000 for Denmark;
(e)
EUR 500 000 for Germany;
(f)
EUR 7 000 for Estonia;
(g)
EUR 60 000 for Ireland;
(h)
EUR 70 000 for Greece;
(i)
EUR 350 000 for Spain;
(j)
EUR 200 000 for France;
(k)
EUR 550 000 for Italy;
(l)
EUR 15 000 for Cyprus;
(m)
EUR 30 000 for Latvia;
(n)
EUR 40 000 for Lithuania;
(o)
EUR for 10 000 Luxembourg;
(p)
EUR 180 000 for Hungary;
(q)
EUR 7 000 for Malta;
(r)
EUR 500 000 for the Netherlands;
(s)
EUR 50 000 for Austria;
(t)
EUR 80 000 for Poland;
(u)
EUR 200 000 for Portugal;
(v)
EUR 400 000 for Romania;
(w)
EUR 55 000 for Slovenia;
(x)
EUR 50 000 for Slovakia;
(y)
EUR 35 000 for Finland;
(z)
EUR 280 000 for Sweden;
(za)
EUR 380 000 for the United Kingdom.
3. The maximum of the costs to be reimbursed to the Member States for the tests covered by the programmes shall on average not exceed:
(a)
ELISA test
EUR 1 per test;
(b)
agar gel immune diffusion test
EUR 1,2 per test;
(c)
HI test for H5/H7
EUR 12 per test;
(d)
virus isolation test
EUR 30 per test;
(e)
PCR test
EUR 15 per test;
(f)
sampling wild birds
EUR 20 per sample.
Transmissible spongiform encephalopathies (TSE), bovine spongiform encephalopathy (BSE) and scrapie
1. The programmes for the monitoring of transmissible spongiform encephalopathies (TSE), and for the eradication of bovine spongiform encephalopathy (BSE) and of scrapie submitted by Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Estonia, Ireland, Greece, Spain, France, Italy, Cyprus, Latvia, Lithuania, Luxembourg, Hungary, Malta, the Netherlands, Austria, Poland, Portugal, Romania, Slovenia, Slovakia, Finland, Sweden, and the United Kingdom are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 100 % of the costs to be incurred by each Member State referred to in paragraph 1 for carrying out rapid tests and primary molecular discriminatory tests and at the rate of 50 % of the cost incurred by each Member State for the compensation to owners for the value of their animals culled and destroyed in accordance with their BSE and scrapie eradication programmes and at a rate of 50 % of the cost of the analysis of samples for genotyping, and shall not exceed:
(a)
EUR 1 850 000 for Belgium;
(b)
EUR 750 000 for Bulgaria;
(c)
EUR 920 000 for the Czech Republic;
(d)
EUR 1 850 000 for Denmark;
(e)
EUR 8 900 000 for Germany;
(f)
EUR 220 000 for Estonia;
(g)
EUR 5 400 000 for Ireland;
(h)
EUR 2 000 000 for Greece;
(i)
EUR 7 400 000 for Spain;
(j)
EUR 12 600 000 for France;
(k)
EUR 4 100 000 for Italy;
(l)
EUR 1 800 000 for Cyprus;
(m)
EUR 230 000 for Latvia;
(n)
EUR 530 000 for Lithuania;
(o)
EUR 105 000 for Luxembourg;
(p)
EUR 990 000 for Hungary;
(q)
EUR 24 000 for Malta;
(r)
EUR 2 900 000 for the Netherlands;
(s)
EUR 1 150 000 for Austria;
(t)
EUR 3 340 000 for Poland;
(u)
EUR 1 300 000 for Portugal;
(v)
EUR 1 300 000 for Romania;
(w)
EUR 250 000 for Slovenia;
(x)
EUR 860 000 for Slovakia;
(y)
EUR 750 000 for Finland;
(z)
EUR 900 000 for Sweden;
(za)
EUR 5 900 000 for the United Kingdom.
3. The financial contribution by the Community to the programmes referred to in paragraph 1 shall be for the tests performed and for the animals culled and destroyed and the maximum amount shall on average not exceed:
(a)
EUR 5 per test, for tests carried out in bovine animals referred to in Annex III to Regulation (EC) No 999/2001;
(b)
EUR 30 per test, for tests carried out in ovine and caprine animals referred to in Annex III to Regulation (EC) No 999/2001;
(c)
EUR 50 per test, for tests carried out in cervid animals referred to in Annex III to Regulation (EC) No 999/2001;
(d)
EUR 175 per test, for primary molecular discriminatory tests carried out as referred to in point 3.2(c)(i) of Chapter C of Annex X to Regulation (EC) No 999/2001;
(e)
EUR 10 per genotyping test;
(f)
EUR 500 per bovine animal;
(g)
EUR 70 per culled sheep or goat.
Rabies
1. The programmes for the eradication of rabies submitted by Bulgaria, Lithuania, Hungary, Austria, Poland, Romania and Slovakia are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out laboratory tests and for the purchase and distribution of vaccine plus baits for the programmes, and shall not exceed,
(a)
EUR 790 000 for Bulgaria;
(b)
EUR 1 100 000 for Lithuania;
(c)
EUR 780 000 for Hungary;
(d)
EUR 270 000 for Austria;
(e)
EUR 4 450 000 for Poland;
(f)
EUR 500 000 for Romania;
(g)
EUR 470 000 for Slovakia.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed:
(a)
for an ELISA test
EUR 8 per test;
(b)
for a test to detect tetracycline in bone
EUR 8 per test.
Enzootic bovine leucosis
1. The programmes for the eradication of enzootic bovine leucosis submitted by Estonia, Lithuania, Malta and Poland are hereby approved for the period from 1 January to 31 December 2009.
2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out laboratory tests and compensation to owners for the value of their animals slaughtered subject to those programmes, and shall not exceed:
(a)
EUR 15 000 for Estonia;
(b)
EUR 20 000 for Lithuania;
(c)
EUR 500 000 for Malta;
(d)
EUR 800 000 for Poland.
3. The maximum of the costs to be reimbursed to the Member States for the programme referred to in paragraph 1 shall on average not exceed:
(a)
for an ELISA test
EUR 0,5 per test;
(b)
for an agar gel immune diffusion test
EUR 0,5 per test;
(c)
for an animal slaughtered
EUR 375 per animal.
Aujeszky’s disease
1. The programmes for the eradication of Aujeszky’s disease submitted by Spain, Hungary and Poland are hereby approved for the period from 1 January 2009 to 31 December 2009.
2. The financial contribution by the Community to the programmes referred to in paragraph 1 shall be at the rate of 50 % of the costs to be incurred by the concerned Member State for the cost of laboratory tests, and shall not exceed:
(a)
EUR 800 000 for Spain;
(b)
EUR 80 000 for Hungary;
(c)
EUR 2 500 000 for Poland.
3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed for an ELISA test EUR 1 per test.
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
